Moderna, Inc. (MRNA)
| Market Cap | 48.20B |
| Revenue (ttm) | 5.15B |
| Net Income (ttm) | -5.97B |
| Shares Out | 383.24M |
| EPS (ttm) | -15.66 |
| PE Ratio | n/a |
| Forward PE | 32.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,073,922 |
| Open | 127.49 |
| Previous Close | 128.32 |
| Day's Range | 124.98 - 128.17 |
| 52-Week Range | 62.55 - 142.79 |
| Beta | 1.57 |
| Analysts | Hold |
| Price Target | 131.57 (+4.62%) |
| Earnings Date | May 2, 2024 |
About MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vac... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $131.57, which is an increase of 4.62% from the latest price.
News
3 Hot Stocks to Buy That Still Look Undervalued
#Morningstar #HotStocks #StockInvesting These top-performing stocks have beaten the market in 2024 yet appear to have more room to run. 00:00 Introduction 00:43 Moderna MRNA 01:27 Hasbro HAS 02:06 Re...
Moderna to Present at Upcoming Conferences in May/June 2024
CAMBRIDGE, MA / ACCESSWIRE / May 13, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Bernstein's 40th Annual Strategic Decisions C...
Moderna Stock Slips as FDA Delays RSV Vaccine Approval
Moderna (MRNA) shares lost ground in intraday trading Friday as the biotech's effort to move beyond just a COVID-19 vaccine was stalled somewhat by U.S. regulators looking at its new shot to treat res...
Moderna says FDA will not complete review of RSV vaccine by May 12 deadline
Moderna Inc.'s stock fell 1.8% early Friday, after the company said the Food and Drug Administration will not complete its review of the company's respiratory syncytial virus, or RSV, vaccine by the o...
US FDA pushes decision on Moderna's RSV vaccine to end of this month
The U.S. Food and Drug Administration has pushed back its decision on Moderna's respiratory syncytial virus (RSV) vaccine by more than two weeks to the end of this month due to some "administrative co...
Moderna says FDA delayed RSV vaccine approval to end of May
The FDA has not informed Moderna of any issues related to the vaccine's safety, efficacy or quality that would prevent its approval, the biotech company said.
Moderna Announces Update on Investigational RSV Vaccine
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024 Agency has indicated it expects to complete...
Moderna's Promise of mRNA Undercut by New RSV Vaccine
Moderna's second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Gerry Smith reports on Bloomberg Televi...
MRNA, GILD: What to Watch in Biotech Stocks
Fiscal discipline is important going forward, notes Hartaj Singh on Moderna (MRNA). He discusses biotech stocks Moderna and Gilead Sciences (GILD).
Largest U.S. Pension Sold Verizon, Disney, and Peloton Stock. It Bought Moderna.
Calpers slashed investments in Verizon, Disney, and Peloton stock, and doubled down on Moderna shares in the first quarter.
Moderna (MRNA) CFO on Earnings & Outlook
Moderna's (MRNA) adjusted EPS came in at -$3.07 versus an estimated -$3.59 and revenue came in at $167.00M versus an estimated $124.74M. CFO Jamey Mock joins Oliver Renick to discuss Moderna's 1Q earn...
Moderna CEO talks Q1 earnings, Brazil COVID vaccine, and cancer treatment markets
Shares of pharmaceutical company Moderna (MRNA) are on the rise despite first quarter losses. Moderna CEO Stéphane Bancel tells Yahoo Finance Senior Reporter Anjalee Khemlani that the company is busy ...
Moderna Focused on Cutting Costs, RSV Vaccine
Moderna Chief Executive Officer Stéphane Bancel talks about how the biotech giant is cutting costs and developing new vaccines. The drugmaker expects to have its vaccine for respiratory syncytial viru...
Moderna CEO Stephane Bancel on Q1 results: The vaccine platform is coming together very nicely
Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, which posted a narrower-than-expected loss for the first quarter as the company's cost-cutting effor...
Moderna loses less than expected as Covid vaccine sales beat estimates - cost cuts take hold
CNBC's Joe Kernen reports on the company's quarterly earnings results.
Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch
Moderna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year, setting a positive tone as it prepares to launch its second product in the U.S. market later this y...
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.
Moderna quarterly sales beat expectations but plummet from previous year
Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher.
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Moderna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine maker looks to launch its second product in the U.S. later this year.
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expec...
Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
CAMBRIDGE, MA / ACCESSWIRE / April 25, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from its respiratory portfolio, including vaccines and vaccine candidates a...
Moderna and OpenAI Collaborate To Advance mRNA Medicine
Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patients Moderna embeds OpenAI's generative AI tools throughout its organization and sees earl...
Pfizer vs Moderna battle over COVID vaccine patents begins in UK
Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
CAMBRIDGE, MA / ACCESSWIRE / April 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a contract with the Ministry of Health in Brazil (Ministério da Saúde) to supply its mRNA COVID-19 vaccine as ...